Nimbus
Oct 15, 2020
Cyclerion’s olinciguat flunks sickle cell test; Nimbus nets $60M; Dyno-Roche’s gene therapy pact; RayzeBio debuts with $ 45M to target tumors
Cyclerion flunks sickle cell test, prompting pivot to CNS disease Cyclerion Therapeutics has terminated the development of olinciguat in sickle cell disease after getting a look at data from a phase 2 trial. The setback caused Cyclerion to switch its focus to IW-6463 and to treat central nervous system diseases....
Read More...
-Agonist.png "Toll-like Receptors Agonist")
